SHINE Technologies Receives European Approval for Innovative Ilumira Leading Nuclear Medicine Advancements
In a significant achievement for nuclear medicine, SHINE Technologies has secured Centralized Marketing Authorization for Ilumira™, which is a non-carrier-added form of lutetium-177 (Lu-177). This approval from the European Medicines Agency (EMA) enables the company to enter one of the world's largest markets for targeted radioligand therapy, which utilizes radioisotopes for cancer treatment.
SHINE Technologies is widely recognized for its pioneering work in fusion technology aimed at producing medical isotopes and advancing towards fusion energy. The approval comes as part of the company's strategy to create an integrated platform that encompasses diagnostic and therapeutic applications of nuclear medicine, thereby serving healthcare providers with comprehensive solutions.
Ilumira is manufactured at SHINE's state-of-the-art facility in Janesville, Wisconsin, known as the Cassiopeia facility. This site is among North America's largest producers of non-carrier-added Lu-177 and employs a proprietary process that ensures consistent and high-quality production. The facility's operations are compliant with current Good Manufacturing Practice (cGMP) and meet the stringent requirements of the European Pharmacopeia standards. With over 99.9% radionuclidic purity and high specific activity, Ilumira stands out from carrier-added alternatives, making it a preferable choice for medical professionals.
Michael Rossi, CEO of SHINE SPECT LLC, expressed excitement over the EMA approval, highlighting how it opens opportunities for the development of advanced radioligand therapies at scale. "For years, our customers have asked for a reliable partner that can deliver both the diagnostic and therapeutic side of nuclear medicine. This approval is a stepping stone towards that realization," Rossi stated, emphasizing the importance of Ilumira in facilitating better patient outcomes.
In addition to this landmark approval, SHINE Technologies has significantly broadened its scope in the field of nuclear medicine through strategic acquisitions and investments. Earlier this year, SHINE expanded its operations by acquiring a U.S. isotopes manufacturing facility, which adds to its portfolio of diagnostic radiopharmaceuticals. This move enables SHINE to provide hospitals and imaging centers with an extensive range of nuclear medicine products, thereby positioning itself as a comprehensive supplier within the sector.
Further reinforcing its growth trajectory, SHINE recently concluded a Series E funding round, securing $240 million led by Dr. Patrick Soon-Shiong. This investment sets the stage for SHINE to enhance the next generation of cancer treatment therapies, further demonstrating its commitment to pushing boundaries in medical science.
Moreover, SHINE is set to develop the Chrysalis facility, which, once completed, will be the largest medical isotope production site globally. Funded in part by a $263 million conditional loan commitment from the U.S. Department of Energy, this fusion-fission hybrid facility will play a crucial role in connecting SHINE's isotope production capabilities with its diagnostic manufacturing processes.
The demand for Lu-177 continues to rise, owing to its crucial role as a nuclear isotope precursor in several approved and investigational therapies for various cancers. Ilumira stands uniquely in this fast-growing market due to its superior purity and concentration, providing a significant advantage over traditional carrier-added alternatives.
With the rigorous standards adhered to in the production of Ilumira, healthcare professionals can rely on SHINE as a trusted partner in incorporating advanced nuclear medicine into their practices. The company’s integrated platform for diagnostic and therapeutic isotopes positions it well for future growth and innovation.
As SHINE continues to expand its global distribution networks and fortify its leadership structure, the medical community can anticipate a wave of advancements in patient treatment options. This recent EMA approval for Ilumira signifies not only a product milestone but also a broader commitment by SHINE Technologies to lead the charge in revolutionizing nuclear medicine.
SHINE Technologies is widely recognized for its pioneering work in fusion technology aimed at producing medical isotopes and advancing towards fusion energy. The approval comes as part of the company's strategy to create an integrated platform that encompasses diagnostic and therapeutic applications of nuclear medicine, thereby serving healthcare providers with comprehensive solutions.
Ilumira is manufactured at SHINE's state-of-the-art facility in Janesville, Wisconsin, known as the Cassiopeia facility. This site is among North America's largest producers of non-carrier-added Lu-177 and employs a proprietary process that ensures consistent and high-quality production. The facility's operations are compliant with current Good Manufacturing Practice (cGMP) and meet the stringent requirements of the European Pharmacopeia standards. With over 99.9% radionuclidic purity and high specific activity, Ilumira stands out from carrier-added alternatives, making it a preferable choice for medical professionals.
Michael Rossi, CEO of SHINE SPECT LLC, expressed excitement over the EMA approval, highlighting how it opens opportunities for the development of advanced radioligand therapies at scale. "For years, our customers have asked for a reliable partner that can deliver both the diagnostic and therapeutic side of nuclear medicine. This approval is a stepping stone towards that realization," Rossi stated, emphasizing the importance of Ilumira in facilitating better patient outcomes.
In addition to this landmark approval, SHINE Technologies has significantly broadened its scope in the field of nuclear medicine through strategic acquisitions and investments. Earlier this year, SHINE expanded its operations by acquiring a U.S. isotopes manufacturing facility, which adds to its portfolio of diagnostic radiopharmaceuticals. This move enables SHINE to provide hospitals and imaging centers with an extensive range of nuclear medicine products, thereby positioning itself as a comprehensive supplier within the sector.
Further reinforcing its growth trajectory, SHINE recently concluded a Series E funding round, securing $240 million led by Dr. Patrick Soon-Shiong. This investment sets the stage for SHINE to enhance the next generation of cancer treatment therapies, further demonstrating its commitment to pushing boundaries in medical science.
Moreover, SHINE is set to develop the Chrysalis facility, which, once completed, will be the largest medical isotope production site globally. Funded in part by a $263 million conditional loan commitment from the U.S. Department of Energy, this fusion-fission hybrid facility will play a crucial role in connecting SHINE's isotope production capabilities with its diagnostic manufacturing processes.
The demand for Lu-177 continues to rise, owing to its crucial role as a nuclear isotope precursor in several approved and investigational therapies for various cancers. Ilumira stands uniquely in this fast-growing market due to its superior purity and concentration, providing a significant advantage over traditional carrier-added alternatives.
With the rigorous standards adhered to in the production of Ilumira, healthcare professionals can rely on SHINE as a trusted partner in incorporating advanced nuclear medicine into their practices. The company’s integrated platform for diagnostic and therapeutic isotopes positions it well for future growth and innovation.
As SHINE continues to expand its global distribution networks and fortify its leadership structure, the medical community can anticipate a wave of advancements in patient treatment options. This recent EMA approval for Ilumira signifies not only a product milestone but also a broader commitment by SHINE Technologies to lead the charge in revolutionizing nuclear medicine.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.